Navigation Links
Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
Date:10/1/2008

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced it has raised $50 million in a private equity financing. This capital will be utilized to support the ongoing Phase 3 development program evaluating linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), to invest in a growing pipeline of internally discovered drug candidates, and to expand commercial capabilities. The financing was led by Morgan Stanley Investment Management, with participation by numerous investors from previous financing rounds.

"Ironwood's investors are terrific and supportive business partners who share our passion for building a great entrepreneurial pharmaceutical company. We are extremely fortunate to work with such high quality investors -- their involvement is a testament to the productivity of our talented team of drug hunters and the strength of our clinical and discovery assets," said Peter Hecht, CEO of Ironwood. "This infusion of equity capital will enable us to execute on our comprehensive development plans for linaclotide, which has the potential to benefit millions of patients; advance our pipeline of therapeutic candidates; and grow our sales and marketing team to commercialize our products."

Ironwood and partner Forest Laboratories, Inc. recently initiated a comprehensive Phase 3 program to evaluate linaclotide's safety and efficacy in patients with either IBS-C or CC. The program will include two pivotal trials in IBS-C patients and two pivotal trials in CC patients, enrolling over 2,500 patients at approximately 250 clinical centers. The companies recently initiated both CC trials and expect to initiate the IBS-C trials by January 2009.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, CC, and other gastrointestinal disorders. In a Phase 2b study in 420 patients with IBS-C, linaclotide
'/>"/>

SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
2. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
3. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
4. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Romark Laboratories Raises $18 Million in Institutional Financing
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. EntreMed Raises $20 Million to Support Clinical Development Program
9. Globus Medical Raises $110 Million in Series E Financing Round
10. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
11. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... 2015  Geneia, a company of experienced healthcare ... improve healthcare efficiencies, today announced a first-of-its-kind partnership ... (BNRC) use Geneia,s advanced analytics solution coupled with ... and lower the cost of patient care. ... and utilization data from multiple sources to create ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Privigen®, the first and only ... proline, is effective and well tolerated in patients ... data presented today at the XIVth Meeting of ... that Privigen offers significant protection against ...
... CHAPEL HILL, N.C., Oct. 6 Pharmaceutical and biotech ... they ensure strong partnerships between R&D and marketing, balancing ... product development. It requires companies to break down the ... instead leverage the strengths of both talented medical researchers ...
Cached Medicine Technology:Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3Creating Partnerships Across R&D and Marketing to Ensure a Successful Global Launch 2
(Date:5/4/2015)... May 04, 2015 The opportunity for children ... life are the motivating forces behind The Fairy Godmother Next ... and author Amy L. Stark. , The inspiration for the ... next door comes from Stark’s desire to be a fairy ... a fairy godmother to my neighbors’ children since they were ...
(Date:5/4/2015)... Now in its seventh year, the ... have made outstanding contributions to the company, to their ... acute and post-acute care settings. The five award categories ... the Year, Advanced Practice Clinician of the Year, Newcomer ... Year. Recipients are selected by IPC’s senior management team. ...
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Jones Arena in Charlottesville, VA. McCartney is one ... music business and this beloved performer continues to roll along ... member of two legendary groups: Wings and The Beatles, has ... since 2013 on the “Out There” tour and has continually ...
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... new, 13,700 square foot facility scheduled to open in ... only provide fertility treatment and services for the center’s ... educational events to a number of local and international ... to their current Carmel Valley/Del Mar location and will ...
(Date:5/4/2015)... May 04, 2015 Elisabeth Rosenthal’s ... a stir and showed the healthcare fraternity as ... healthcare procedure, the downside of balance billing. In ... healthcare provider billing a patient for the difference ... reimburse and what the provider chooses to charge. ...
Breaking Medicine News(10 mins):Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3
... Goodwin HealthDay Reporter , MONDAY, Dec. 12 (HealthDay ... other children, a finding that researchers say may provide a ... see. Blinking is largely an involuntary process that helps ... that your eyes are closed, you are temporarily blinded. And ...
... US Prostate Cancer Prevention Trial found cancer in many men ... which PSA level should lead to a biopsy recommendation. ... considerable controversy, that the evidence does not support recommending PSA ... the risks outweigh the benefits. Now, a study shows ...
... News) -- ,Cancer patients receiving chemotherapy most often develop ... according to a large new study. Efforts to ... treatment should focus on outpatients -- not those still ... blood clot, also called a venous thromboembolism (VTE), is ...
... retrospective study shows that children of childhood cancer survivors ... ovaries and/or chemotherapy with alkylating agents do not have ... of survivors who did not have such cancer treatment. ... defects are unlikely for cancer survivors who are concerned ...
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she ... pound, Madeline Mann was the world,s smallest surviving baby. At ... of world,s tiniest infant, weighing in at 0.57 pounds. She was ... in the neonatal intensive care unit at Loyola University Medical Center ...
... , MONDAY, Dec. 12 (HealthDay News) -- The poet Emily ... that she "never met this fellow/Attended or alone/Without a tighter ... in her ophidiophobia (fear of snakes) and, it turns out, ... it is found in the grass or elsewhere. A ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Cancer Outpatients at Greater Risk for Blood Clots 2Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 2Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 3Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 4Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Snakes Make Your Skin Crawl? Study Suggests Why 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: